Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 837.60M | $ 753.20M | $ 678.40M | $ 690.60M | $ 557.00M |
| Gross Profit | $ 585.40M | $ 517.00M | $ 476.40M | $ 493.00M | $ 378.80M |
| Operating Income | $ -123.50M | $ -257.40M | $ -140.60M | $ -190.50M | $ -194.80M |
| EBITDA | $ -59.50M | $ -197.40M | $ -84.70M | $ 12.30M | $ -123.40M |
| Net Income | $ -127.30M | $ -263.30M | $ -112.00M | $ -27.20M | $ -223.70M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 102.40M | $ 140.90M | $ 114.90M | $ 339.80M | $ 150.70M |
| Total Assets | $ 1.03B | $ 1.15B | $ 1.20B | $ 1.32B | $ 1.42B |
| Total Debt | $ 140.30M | $ 152.10M | $ 145.00M | $ 92.30M | $ 289.00M |
| Net Debt | $ 37.90M | $ 20.00M | $ 88.10M | $ -166.10M | $ 172.00M |
| Total Liabilities | $ 326.50M | $ 363.30M | $ 312.90M | $ 352.90M | $ 537.80M |
| Stockholders' Equity | $ 701.10M | $ 783.20M | $ 885.80M | $ 967.80M | $ 881.00M |
| Cash Flow | |||||
| Free Cash Flow | $ -38.40M | $ -184.20M | $ -151.60M | $ 600.00K | $ -40.10M |
| Operating Cash Flow | $ -8.70M | $ -110.90M | $ -106.30M | $ 18.60M | $ -26.90M |
| Investing Cash Flow | $ -11.90M | $ 31.90M | $ -77.50M | $ 274.40M | $ 61.60M |
| Financing Cash Flow | $ -7.40M | $ 152.90M | $ -8.00M | $ -150.60M | $ -1.00M |